SPC365

Bridging the Gender Gap in TAVI: Real-World Evidence from a Single-Center Study

Session: SESSÃO DE POSTERS 17 - DIFERENÇAS ENTRE SEXOS NA MEDICINA CARDIOVASCULAR
Speaker: Rita Louro

Congress: CPC 2025
Topic: K. Cardiovascular Disease In Special Populations
Theme: 30. Cardiovascular Disease in Special Populations
Subtheme: 30.2 Cardiovascular Disease in Women
Session Type: Cartazes
FP Number: ---
Authors: Rita Louro; António Almeida; Orlando Luquengo; Rafael Viana; Marta Figueiredo; Miguel Carias; Marisa Serrano; Gustavo Sá Mendes; David Neves; Ângela Bento; Renato Fernandes; Lino Patrício

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>BACKGROUND: </strong></span></span></span></p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><span style="font-family:&quot;Aptos Light&quot;,sans-serif">Women are commonly underrepresented in clinical trials, raising concerns about the applicability of data to the female population. In this analysis, we sought to address whether the results observed in clinical trials align with real-world practice and whether women face distinct challenges or benefits following TAVI compared to men.</span></span></span></span></p>

<p style="text-align:justify">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>METHODS: </strong></span></span></span></p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><span style="font-family:&quot;Aptos Light&quot;,sans-serif">This retrospective analysis assessed 300 TAVI patients from a single centre, w</span><span style="font-family:&quot;Aptos Light&quot;,sans-serif">ithout surgical backup.</span> <span style="font-family:&quot;Aptos Light&quot;,sans-serif">We aimed to </span><span style="font-family:&quot;Aptos Light&quot;,sans-serif">assess in-hospital outcomes: periprosthetic leak, high-grade atrioventricular block, vascular and haemorrhagic complications, stroke, acute kidney injury, and death within 7 days. At 1 year follow-up (FUP) outcomes were cardiovascular death, readmission for cardiovascular causes, and clinical improvement following TAVI. </span></span></span></span></p>

<p style="text-align:start">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>RESULTS: </strong></span></span></span></p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><span style="font-family:&quot;Aptos Light&quot;,sans-serif">From a total of 300 patients undergoing TAVI, 139 were male and 161 were women. Regarding baseline characteristics, w</span><span style="font-family:&quot;Aptos Light&quot;,sans-serif">omen were older than men. Diabetes was more prevalent in men, as was current smoking. Men had a higher prevalence of coronary artery disease (CAD), previous PCI and previous CABG. Renal dysfunction was more common in women. About clinical presentation, women had higher risk scores, higher mean aortic valve gradients, lower aortic valve area, higher left ventricular ejection fraction and </span><span style="font-family:&quot;Aptos Light&quot;,sans-serif">higher median calcium score</span><span style="font-family:&quot;Aptos Light&quot;,sans-serif">. Men and women had no significant differences in in-hospital complications, except for acute kidney injury more frequent in women. At 1-year follow-up, no significant differences were found according to sex</span> <span style="font-family:&quot;Aptos Light&quot;,sans-serif">concerning cardiovascular death, readmissions due to cardiovascular causes, or clinical improvement (p &gt; 0.05 for all).</span></span></span></span></p>

<p style="text-align:start">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Aptos,sans-serif"><span style="color:#000000"><strong>CONCLUSIONS</strong><span style="font-family:&quot;Aptos Light&quot;,sans-serif">: </span></span></span></span></p>

<p><span style="font-size:12pt"><span style="color:#000000"><span style="font-family:&quot;Aptos Light&quot;,sans-serif">In contrast to clinical trials, women were well-represented in our study population. Women tended to present with more severe valvular disease and higher surgical risk scores compared to men. However, men exhibited a higher prevalence of comorbidities such as coronary artery disease and previous revascularization procedures (PCI and CABG). Despite these baseline differences, no significant disparities were observed between genders in most in-hospital complications and 1-year follow-up outcomes, except for acute kidney injury, which was more frequent in women. This suggests that, despite their higher initial surgical risk, women achieve similar clinical outcomes to men after TAVI.</span></span></span></p>